Table 1.
Patient demographics and baseline characteristics
| Patients (N = 157) | |
|---|---|
| Sex, n (%) | |
| Female | 81 (52) |
| Male | 76 (48) |
| Age at diagnosis (years) | |
| Median (range) | 66 (18-91) |
| Tumor type, n (%) | |
| Melanoma | 56 (35.7) |
| Endometrial | 24 (15.3) |
| Lung adenocarcinoma | 20 (12.7) |
| Colon | 8 (5.1) |
| Skin squamous cell | 7 (4.5) |
| Lung squamous cell | 7 (4.5) |
| Urothelial | 5 (3.2) |
| Unknown primary squamous cell | 4 (2.5) |
| Cervical squamous cell | 2 (1.3) |
| Uterine carcinosarcoma | 2 (1.3) |
| Small-cell lung cancer | 2 (1.3) |
| Large-cell neuroendocrine | 2 (1.3) |
| Prostate | 2 (1.3) |
| Unknown primary | 2 (1.3) |
| Ovarian | 2 (1.3) |
| Gastric | 2 (1.3) |
| Uterine leiomyosarcoma | 1 (0.6) |
| Breast | 1 (0.6) |
| Glioblastoma | 1 (0.6) |
| Clear cell endometrial | 1 (0.6) |
| Head and neck | 1 (0.6) |
| Kidney sarcomatoid | 1 (0.6) |
| Merkel cell | 1 (0.6) |
| Small intestine | 1 (0.6) |
| Pancreatobiliary | 1 (0.6) |
| Soft tissue sarcoma | 1 (0.6) |
| Adrenal gland | 1 (0.6) |
| Treatmenta, n (%) | |
| Prior radiotherapy | 56 (35.7) |
| Adjuvant therapy | 34 (21.7) |
| Immunotherapy | 59 (37.6) |
| Chemotherapy | 54 (34.4) |
| Genomic status,an (%) | |
| MSI-H | 35 (22.3) |
| TMB-H | 149 (94.9) |
| TMB-H and MSI-H | 27 (17.2) |
MSI-H, microsatellite instability-high; TMB-H, tumor mutational burden-high.
a
Patients may fall into more than one category.